drugset / Trial / NCT04622358

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

NCT04622358

Phase 1 Completed 43 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.

Timeline

Start
2020-12-05
Primary completion
2021-03-08
Completion
2021-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-214-02 Unknown
Subject Rabeprazole Small molecule